Assignee
MARENGO THERAPEUTICS INC
US·13 granted patents·27 pending applications·39 citations·filing 2017–2025
Top patents by PatentIndex Score
40 records- 0196US11291721B2Multispecific and multifunctional molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2017·Granted Apr 5, 2022·15 cites·22 claims
- 0295US11965025B2Method of treating solid cancers with bispecific interleukin-anti-TCRß moleculesMARENGO THERAPEUTICS INC·Filed 2022·Granted Apr 23, 2024·7 cites·26 claims
- 0393US11845797B2Anti-TCR antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2019·Granted Dec 19, 2023·7 cites·34 claims
- 0492US12351632B2Anti-TCR antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2023·Granted Jul 8, 2025·1 cites·33 claims
- 0591US12486326B2Anti-TCR antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2023·Granted Dec 2, 2025·1 cites·10 claims
- 0691US12286477B2Anti-TCR antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2022·Granted Apr 29, 2025·1 cites·29 claims
- 0786US2024301060A1Anti-tcr antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0884US12152073B2Multifunctional molecules that bind to calreticulin and uses thereofMARENGO THERAPEUTICS INC·Filed 2019·Granted Nov 26, 2024·4 cites·20 claims
- 0983US12384842B2Antibody molecules that bind to NKP30 and uses thereofMARENGO THERAPEUTICS INC·Filed 2021·Granted Aug 12, 2025·1 cites·23 claims
- 1082US2025340640A1Anti-tcr antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1182US2026022173A1Anti-tcr antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1280US12247060B2Calreticulin binding constructs and engineered T cells for the treatment of diseasesMARENGO THERAPEUTICS INC·Filed 2019·Granted Mar 11, 2025·1 cites·24 claims
- 1378US2025215085A1Anti-tcr antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1477US2022064297A1Anti-tcr antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1574US11673971B2Multispecific antibody molecules comprising lambda and kappa light chainsMARENGO THERAPEUTICS INC·Filed 2017·Granted Jun 13, 2023·1 cites·10 claims
- 1674US2025074998A1Multifunctional molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1772US12421323B2Multispecific antibody molecules comprising lambda and kappa light chainsMARENGO THERAPEUTICS INC·Filed 2023·Granted Sep 23, 2025·0 cites·13 claims
- 1870US2023227552A1Anti-tcr antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1966US2024409636A1Multifunctional molecules binding to tcr and uses thereofMARENGO THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2066US2022288200A1Multispecific and multifunctional molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2164US2025011459A1Multifunctional molecules comprising g6b binder and/or cd34 binder and uses thereofMARENGO THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2263US2025333500A1Multifunctional molecules that bind to t cell related cancer cells and uses thereofMARENGO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2363US2024002543A1Multifunctional molecules that bind to calreticulin and uses thereofMARENGO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2463US2023348593A1Antibody molecules that bind to nkp30 and uses thereofMARENGO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2562US2023192848A1Engineered cell compositions and methods of use thereofMARENGO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2661US12358982B2Multifunctional molecules that bind to T cell related cancer cells and uses thereofMARENGO THERAPEUTICS INC·Filed 2021·Granted Jul 15, 2025·0 cites·23 claims
- 2761US2024400990A1Immune cell populations and uses thereofMARENGO THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2861US2023048244A1Anti-tcr antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2959US2021380692A1Anti-tcr antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3058US2023333112A1Methods of detecting trbc1 or trbc2MARENGO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3157US2025099579A1Multispecific molecules binding to tcr and uses thereofMARENGO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3257US2023102344A1Multifunctional molecules that bind to cd33 and uses thereofMARENGO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3357US2022064255A1Anti-tcr antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3455US2023357395A1Multifunctional molecules that bind to t cell related cancer cells and uses thereofMARENGO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3554US2025297008A1Multifunctional molecules binding to tcr and uses thereofMARENGO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3652US2021380670A1Multifunctional molecules that bind to calreticulin and uses thereofMARENGO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3751US2021380691A1Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disordersMARENGO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3846US2025297007A1Multifunctional molecules binding to tcr and uses thereofMARENGO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3946US2022242957A1Csf1r/ccr2 multispecific antibodiesMARENGO THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4044US12134654B2Multispecific molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2018·Granted Nov 5, 2024·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when MARENGO THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →